Tilray, Inc. TLRY said Thursday that it has received approval from the United State government to import CBD and has successfully brought in a shipment to support two New York University School of Medicine clinical trials.
The trials aim to test CBD as a treatment for patients with alcohol use disorder, or AUD, and post-traumatic stress disorder with AUD.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
Tilray’s GMP-certified, capsule-based CBD formulation will be used in the studies.
The double-blind studies will be led by NYU psychiatry professor Michael Bogenschutz, M.D. and Charles Marmar, M.D., the Lucius N. Littauer professor of psychiatry and chair of the department of psychiatry at NYU.
Bogenschutz will oversee the study on AUD. Marmar will lead the AUD and PTSD study.
Recruitment for both trials is expected to begin this summer.
Tilray shares were trading higher by 1.26% at $42.46 at the time of publication Thursday.
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!